

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :
Robert G. Aslanian et al :
:
For Patent For: Examiner: To be assigned
Novel Non-Imidazole Compounds :
Art Unit: To be assigned
Serial No.: To be assigned :
Filing Date: To be assigned :
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98.
Applicants enclose a Form PTO-1449 (one page) listing publications known to
applicants that may be relevant to this application.

This Statement accompanies the divisional application on filing.


Publications AA-AH, AL-AO and AQ-AY were cited either in the background portion
of the specification or in the examples. It is noted that AV is an English abstract of a
Hungarian journal article referred to in the application. Publications AP, AZ and BQ
were cited during the prosecution of the parent application. Publication BL on the
attached PTO Form-1449 is the published PCT equivalent of reference cited as AZ
in the parent application.

Publications AI, AJ, and AK are later-filed, co-owned, co-pending US applications,
none of which have been published at this date.

Copies of newly cited AI, AJ, AK and BL are provided. Copies of the remaining
references are not provided since they should be available in the file of the parent
application. The examiner is requested to contact the undersigned attorney if copies
of any of the references are not available.

The examiner is requested to examine the publications, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

Respectfully submitted,



Anita W. Magatti
Reg. No. 29,825
Attorney for Applicants
(908) 298-5067

10/31/03

Date

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: AL01348K1B		SERIAL NO.: To be assigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: Robert G. Aslanian et al.			
(Use several sheets if necessary)					FILING DATE: To be assigned		GROUP: To be assigned	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA	5,869,479	02/09/99	William Kreutner et al.	514	212		
	AB	5,463,074	10/31/95	Neng-Yang Shih et al.	548	314.7		
	AC	5,578,616	11/26/96	Robert G. Aslanian et al.	514	341		
	AD	5,633,250	05/27/97	Neng-Yang Shih	514	218		
	AE	5,807,872	09/15/98	Neng-Yang Shih et al.	514	326		
	AF	5,990,147	11/23/99	Robert G. Aslanian	514	400		
	AG	6,034,251	03/07/00	Robert G. Aslanian et al.	548	338.1		
	AH	6,100,279	08/08/00	Wayne D. Vaccaro et al.	514	326		
	AI	10/417,391	Filed 4/16/03	Zeng et al				
	AJ	10/414,943	Filed 4/16/03	Ting et al				
	AK	10/600,674	Filed 6/20/03	Aslanian et al				
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	AL	WO 95/14007	26/05/95	WIPO				
	AM	WO 99/24405	20/05/99	WIPO				
	AN	WO 98/06394	19/02/98	WIPO				
	AO	0 407 217 A1	06/07/90	EPO				
	AP	WO 97/19074	5/29/97	WIPO				
	BL	WO 02/072570	9/19/02	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AQ	European Journal of Pharmacology Vol. 294 (1995) 329-335						
	AR	The Journal of Organic Chemistry, Vol. 33, No. 6, June 1968, pgs. 2388-2392						
	AS	Journal of Medicinal Chemistry, Vol. 19, 1976, pgs. 360-365						
	AT	J. Heterocyclic Chem., 3 (1960) pgs. 252-256						
	AU	Journal of Medicinal Chemistry, 37(16), (1994), pgs. 2537-2551						
	AV	T. Zsuzsanna, Hung. Magy. Kem Foly. 74(3) (1968) pgs. 116-119						
	AW	Journal of Medicinal Chemistry, 43(12), (2000), pgs. 2362-2370						
	AX	Arch. Pharm. Pharm. Med. Chem. 332 (1999), pgs. 389-398						
	AY	Arch. Pharm. Pharm. Med. Chem. 331 (1998), pgs. 395-404						
	AZ	Leurs et al, TIPS, Vol. 19, May 1998, pgs. 177-183.						
	BQ	Bakker et al, Clin. Allergy Immuno., Vol. 17 (2002), pgs. 27-64.						
EXAMINER					DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								